Last reviewed · How we verify
YY-20394
At a glance
| Generic name | YY-20394 |
|---|---|
| Also known as | Linperlisib, Gemcitabine, Oxaliplatin |
| Sponsor | Shanghai YingLi Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL (PHASE1, PHASE2)
- A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies (PHASE1)
- Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma (PHASE1, PHASE2)
- A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma (PHASE4)
- Real World Study of Linperlisib for Lymphoma Treatment
- A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma (PHASE2)
- SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma (PHASE2)
- A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YY-20394 CI brief — competitive landscape report
- YY-20394 updates RSS · CI watch RSS
- Shanghai YingLi Pharmaceutical Co. Ltd. portfolio CI